Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 1
1987 1
1993 3
1994 2
1996 1
1997 1
1998 2
1999 4
2000 2
2001 5
2002 1
2003 2
2004 1
2005 5
2006 11
2007 10
2008 13
2009 12
2010 15
2011 11
2012 28
2013 25
2014 34
2015 27
2016 49
2017 29
2018 45
2019 58
2020 72
2021 84
2022 81
2023 85
2024 105
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

738 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH; ESCORT-1st Investigators. Luo H, et al. Among authors: ba y. JAMA. 2021 Sep 14;326(10):916-925. doi: 10.1001/jama.2021.12836. JAMA. 2021. PMID: 34519801 Free PMC article. Clinical Trial.
Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy.
Long H, Jia Q, Wang L, Fang W, Wang Z, Jiang T, Zhou F, Jin Z, Huang J, Zhou L, Hu C, Wang X, Zhang J, Ba Y, Gong Y, Zeng X, Zeng D, Su X, Alexander PB, Wang L, Wang L, Wan YY, Wang XF, Zhang L, Li QJ, Zhu B. Long H, et al. Among authors: ba y. Cancer Cell. 2022 Jun 13;40(6):674-693.e7. doi: 10.1016/j.ccell.2022.04.018. Epub 2022 May 19. Cancer Cell. 2022. PMID: 35594863 Free article.
Pan-cancer analysis of G6PD carcinogenesis in human tumors.
Liu B, Fu X, Du Y, Feng Z, Chen R, Liu X, Yu F, Zhou G, Ba Y. Liu B, et al. Among authors: ba y. Carcinogenesis. 2023 Aug 18;44(6):525-534. doi: 10.1093/carcin/bgad043. Carcinogenesis. 2023. PMID: 37335542
Associations Between Life's Essential 8 and Chronic Kidney Disease.
Ren Y, Cai Z, Guo C, Zhang Y, Xu H, Liu L, Wang L, Ba Y, Liu S, Zhang G, Liu Z, Han X. Ren Y, et al. Among authors: ba y. J Am Heart Assoc. 2023 Dec 19;12(24):e030564. doi: 10.1161/JAHA.123.030564. Epub 2023 Dec 8. J Am Heart Assoc. 2023. PMID: 38063194 Free PMC article.
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.
Peng Z, Liu T, Wei J, Wang A, He Y, Yang L, Zhang X, Fan N, Luo S, Li Z, Gu K, Lu J, Xu J, Fan Q, Xu R, Zhang L, Li E, Sun Y, Yu G, Bai C, Liu Y, Zeng J, Ying J, Liang X, Xu N, Gao C, Shu Y, Ma D, Dai G, Li S, Deng T, Cui Y, Fang J, Ba Y, Shen L. Peng Z, et al. Among authors: ba y. Cancer Commun (Lond). 2021 Nov;41(11):1173-1182. doi: 10.1002/cac2.12214. Epub 2021 Oct 19. Cancer Commun (Lond). 2021. PMID: 34665942 Free PMC article. Clinical Trial.
738 results